This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Drug Stocks Poised to Stage Comeback

NEW YORK ( TheStreet) -- Health-care stocks, especially drug shares, performed downright sickly in 2010. That could change this year, as some fund managers say overlooked and undervalued companies may finally provide healthy returns.

The Healthcare SPDR ETF (XLV) rose barely 1% in 2010, compared with a 13% jump in the S&P 500 Index. The largest holdings of the Healthcare SPDR are Johnson & Johnson (JNJ - Get Report) (13.5%), Pfizer (PFE - Get Report) (11.5%) and Merck (MRK - Get Report) (9%). They all finished in the red last year, helping to make health care the worst-performing sector in the S&P 500.

Russell Croft, manager of the Croft Value Fund (CLVFX), says some drug stocks provide stability because they're cheap, pay big dividends and have strong balance sheets. A catalyst, he says, are companies benefiting from emerging markets, where a growing middle class is able to pay for drug therapies.

Bob Auer of the Auer Growth Fund (AUERX) says some mid-cap or second-tier pharma stocks can easily get a boost by a "new product or something exciting can move the needle."

TheStreet searched for 2011's most dynamic drug stocks with Auer and Croft.

Johnson & Johnson (JNJ - Get Report)

Johnson & Johnson is a diversified manufacturer of health-care products including pharmaceuticals, consumer products and medical devices. Due to their vast product portfolio, huge scale and the defensive nature of the industry, J&J is a relatively stable investment in any economic environment, says Croft. Half of sales come from abroad, and they will benefit from faster-growth emerging markets over the next decade.

Croft also likes the company's AAA-rated balance sheet, which is one of the strongest across any industry, with $22 billion in cash and about $12 billion in debt. J&J is in the middle of an extensive cost-cutting program that consists of consolidating pharmaceutical operations, integrating the medical-device business and improving efficiency across the entire company, which should combine to yield up to $1.6 billion to the bottom line.

"Their pharmaceutical pipeline is one of the best in the group and new products could add an estimated $5 billion to segment sales by 2013. New products will contribute over $1.5 billion to segment sales this year from launches of Stelara, Simponi, Sustenna and Nucynta," says Croft.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
XLV $71.95 0.54%
JNJ $102.00 -0.04%
MNTA $17.97 1.10%
MRK $53.72 0.46%
PFE $32.87 2.82%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs